Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Pyrrolidone derivatives
Autore:
Shorvon, S;
Indirizzi:
Natl Neurol Inst, Singapore 308433, Singapore Natl Neurol Inst SingaporeSingapore 308433 Singapore 308433, Singapore Univ Coll London, Natl Hosp Neurol & Neurosurg, Inst Neurol, Dept Clin Neurol, London WC1, England Univ Coll London London England WC1 ept Clin Neurol, London WC1, England
Titolo Testata:
LANCET
fascicolo: 9296, volume: 358, anno: 2001,
pagine: 1885 - 1892
SICI:
0140-6736(200112)358:9296<1885:PD>2.0.ZU;2-5
Fonte:
ISI
Lingua:
ENG
Soggetto:
LEVETIRACETAM UCB L059; REFRACTORY PARTIAL SEIZURES; AMPA RECEPTOR MODULATORS; ADD-ON THERAPY; DOUBLE-BLIND; ALZHEIMERS-DISEASE; IN-VIVO; SYNAPTIC TRANSMISSION; ANTICONVULSANT DRUG; ANTIEPILEPTIC DRUGS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
93
Recensione:
Indirizzi per estratti:
Indirizzo: Shorvon, S Natl Neurol Inst, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore Natl Neurol Inst 11 Jalan Tan Tock Seng Singapore Singapore 308433
Citazione:
S. Shorvon, "Pyrrolidone derivatives", LANCET, 358(9296), 2001, pp. 1885-1892

Abstract

The pyrrolidone (2-oxopyrrolidine) family of chemicals has been the subject of research for mare than three decades. Experimental and clinical work first focused on their so-called nootropic effects; later name the possibilities for neuroprotection after stroke and use as antiepileptic agents. Piracetam, the first of the class, was developed by pioneering research by C Giurgea in the late 1960s, and it was he who coined the term "nootropic", to mean enhancement of learning and memory. The term is sometimes extended to include other actions such as neuroprotection. These properties, together with the lack of other generally adverse psychopharmacological actions (eg, sedation, analgesia, or motor or behavioural changes), distinguish the pyrrolidones from other psychoactive drug classes. The mechanisms of action of these drugs are still not fully established; indeed, different compounds inthis class may have different modes of action. Interest in this drug classhas recently been reawakened by the licensing of levetiracetam as a potentially major new antiepileptic drug and of piracetam for its antimyoclonic action and effects after stroke and in mild cognitive impairment. Other drugs in this class are currently at an advanced stage of development, and the renewal of interest in this therapeutic area is likely to mean not only that more pyrrolidones will enter clinical practice in the next few years but also that the clinical indications of drugs already licensed will widen.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 22/09/20 alle ore 04:23:16